Farmax India Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported loss from operations before other income, provisions and exceptional items of INR 6.558 million compared to INR 8.060 million a year ago. Loss from ordinary activities before tax was INR 6.558 million compared to INR 8.060 million a year ago. Net loss was INR 6.558 million or INR 0.01 per basic and diluted share before and after extraordinary items (not annualized) compared to INR 8.060 million or INR 0.02 per basic and diluted share before and after extraordinary items (not annualized) a year ago. For the nine months, the company reported total income from operations (net) of INR 0.871 million compared to INR 43.284 million a year ago. Loss from operations before other income, provisions and exceptional items was INR 9.732 million compared to INR 24.895 million a year ago. Loss from ordinary activities before tax was INR 9.732 million compared to INR 24.464 million a year ago. Net loss was INR 9.732 million or INR 0.06 per basic and diluted share before and after extraordinary items (not annualized) compared to INR 24.464 million or INR 0.05 per basic and diluted share before and after extraordinary items (not annualized) a year ago.